ACW ACW XanaCIDD phase 2a trial topline results 12/08/24 PRICE SENSITIVE download Created with Sketch. 1.1MB Share ACW Trading Halt 08/08/24 PRICE SENSITIVE download Created with Sketch. 664.71KB Share ACW ACW June 2024 quarterly activity report & Appendix 4C 22/07/24 PRICE SENSITIVE download Created with Sketch. 590.63KB Share ACW ACW XanaCIDD depression trial results expected early August 02/07/24 PRICE SENSITIVE download Created with Sketch. 248.15KB Share ACW Positive Xanamem biomarker trial published in Jnl Alz Dis 26/06/24 PRICE SENSITIVE download Created with Sketch. 317.48KB Share ACW ACW Oversubscribed $3.9 million entitlement offer completed 05/06/24 PRICE SENSITIVE download Created with Sketch. 218.56KB Share ACW Actinogen entitlement offer closed and oversubscribed 30/05/24 PRICE SENSITIVE download Created with Sketch. 240.11KB Share ACW Prospectus - Non-renounceable Entitlement Offer 07/05/24 PRICE SENSITIVE download Created with Sketch. 470.52KB Share ACW Actinogen announces capital raising of up to $8.9 million 03/05/24 PRICE SENSITIVE download Created with Sketch. 2.68MB Share ACW Trading Halt 01/05/24 PRICE SENSITIVE download Created with Sketch. 333.62KB Share ACW ACW March 2024 quarterly activity report & Appendix 4C 30/04/24 PRICE SENSITIVE download Created with Sketch. 592.09KB Share ACW ACW completes cognition & depression phase 2 trial enrolment 22/04/24 PRICE SENSITIVE download Created with Sketch. 244.8KB Share ACW First patient treated in ACW XanaMIA ph 2b Alzheimers trial 15/04/24 PRICE SENSITIVE download Created with Sketch. 238.21KB Share ACW Actinogen HY2024 financial results two key phase 2 trial 26/02/24 PRICE SENSITIVE download Created with Sketch. 256.58KB Share ACW Actinogen HY2024 financial report and Appendix 4D 26/02/24 PRICE SENSITIVE download Created with Sketch. 2.75MB Share ACW Response to ASX Aware Query 20/02/24 PRICE SENSITIVE download Created with Sketch. 934.62KB Share ACW Actinogen awarded UK Innovation Passport for Xanamem 15/02/24 PRICE SENSITIVE download Created with Sketch. 242.2KB Share ACW ACW December 2023 quarterly activity report & Appendix 4C 30/01/24 PRICE SENSITIVE download Created with Sketch. 510KB Share ACW Actinogen receives $4.8 million R&D tax incentive rebate 28/11/23 PRICE SENSITIVE download Created with Sketch. 224.74KB Share ACW Actinogen September quarterly activity report & Appendix 4C 16/10/23 PRICE SENSITIVE download Created with Sketch. 511.35KB Share ACW Actinogen enhances XanaMIA Phase 2b Alzheimers trial 26/09/23 PRICE SENSITIVE download Created with Sketch. 219.7KB Share ACW Actinogen closes successful $10 million rights issue offer 07/09/23 PRICE SENSITIVE download Created with Sketch. 218.02KB Share ACW Actinogen FY2023 results, following the science 30/08/23 PRICE SENSITIVE download Created with Sketch. 269.85KB Share ACW ACW Appendix 4E and 2023 Annual Report 30/08/23 PRICE SENSITIVE download Created with Sketch. 4.11MB Share ACW ACW secures further $0.5m rights issue shortfall commitment 30/08/23 PRICE SENSITIVE download Created with Sketch. 224.98KB Share ACW ACW secures shortfall commitments of $4.56m for rights issue 15/08/23 PRICE SENSITIVE download Created with Sketch. 222.88KB Share ACW Entitlement Offer Prospectus 08/08/23 PRICE SENSITIVE download Created with Sketch. 1.26MB Share ACW Actinogen announces $10 million rights offer 02/08/23 PRICE SENSITIVE download Created with Sketch. 259.74KB Share ACW Quarterly Activity Report & Appendix 4C 31/07/23 PRICE SENSITIVE download Created with Sketch. 330.43KB Share ACW Trading Halt 31/07/23 PRICE SENSITIVE download Created with Sketch. 642.62KB Share ACW ACW AD trial amendment and Clinical Science Forum slides 24/05/23 PRICE SENSITIVE download Created with Sketch. 1.69MB Share ACW Quarterly Activity Report & Appendix 4C 24/04/23 PRICE SENSITIVE download Created with Sketch. 325.71KB Share ACW Appendix 4D & Half-Year Financial Statements 22/02/23 PRICE SENSITIVE download Created with Sketch. 1.33MB Share ACW Quarterly Activity Report & Appendix 4C 30/01/23 PRICE SENSITIVE download Created with Sketch. 389.51KB Share ACW FDA agrees to six-month Phase 2b Alzheimers Disease Trial 22/12/22 PRICE SENSITIVE download Created with Sketch. 235.52KB Share ACW First patient treated in XanaCIDD Phase 2 Depression Trial 08/12/22 PRICE SENSITIVE download Created with Sketch. 230.87KB Share ACW Quarterly Activity Report & Appendix 4C 28/10/22 PRICE SENSITIVE download Created with Sketch. 489.86KB Share ACW R&D tax incentive rebate received 20/10/22 PRICE SENSITIVE download Created with Sketch. 204.95KB Share ACW ACW clinical biomarker study webcast presentation 10/10/22 PRICE SENSITIVE download Created with Sketch. 2.4MB Share ACW ACW announces positive Alzheimers Disease clinical results 10/10/22 PRICE SENSITIVE download Created with Sketch. 300.23KB Share ACW Trading Halt 06/10/22 PRICE SENSITIVE download Created with Sketch. 272.6KB Share ACW Actinogen FY22 Results - Accelerating Clinical Development 25/08/22 PRICE SENSITIVE download Created with Sketch. 254.15KB Share ACW ACW Appendix 4E and 2022 Annual Report 25/08/22 PRICE SENSITIVE download Created with Sketch. 4.92MB Share ACW Quarterly Activity Report & Appendix 4C 28/07/22 PRICE SENSITIVE download Created with Sketch. 348.85KB Share ACW ACW announces Phase 2 trial designs for AD & MDD 14/06/22 PRICE SENSITIVE download Created with Sketch. 556.64KB Share ACW Actinogen trial results & strategic update presentation 04/05/22 PRICE SENSITIVE download Created with Sketch. 2.29MB Share ACW Actinogen prioritizes Alzheimers Disease & Depression 04/05/22 PRICE SENSITIVE download Created with Sketch. 243.81KB Share ACW Quarterly Activity Report & Appendix 4C 28/04/22 PRICE SENSITIVE download Created with Sketch. 814.14KB Share ACW ACW positive XanaMIA results webcast slide presentation 27/04/22 PRICE SENSITIVE download Created with Sketch. 2.07MB Share ACW ACW announces positive XanaMIA results for Xanamem 27/04/22 PRICE SENSITIVE download Created with Sketch. 250.85KB Share ACW Trading Halt 22/04/22 PRICE SENSITIVE download Created with Sketch. 679.48KB Share ACW Appendix 4D & Half-Year Financial Statements 24/02/22 PRICE SENSITIVE download Created with Sketch. 975.13KB Share ACW Actinogen XanaMIA Part A trial results expected in April 11/02/22 PRICE SENSITIVE download Created with Sketch. 256.29KB Share ACW Actinogen appoints XanaFX Phase 2 trial manager 09/02/22 PRICE SENSITIVE download Created with Sketch. 259.28KB Share ACW Quarterly Activity Report & Appendix 4C 28/01/22 PRICE SENSITIVE download Created with Sketch. 496.77KB Share ACW Capital Raising Completion 20/12/21 PRICE SENSITIVE download Created with Sketch. 236KB Share ACW ACW Strategic Collaboration with Oxford Uni Researchers 07/12/21 PRICE SENSITIVE download Created with Sketch. 180.98KB Share ACW XanaMIA Part A trial achieves target enrolment 29/11/21 PRICE SENSITIVE download Created with Sketch. 204.1KB Share ACW Strategic Update & Capital Raising Investor Presentation 25/11/21 PRICE SENSITIVE download Created with Sketch. 6.5MB Share ACW Program Expansion & Capital Raising 25/11/21 PRICE SENSITIVE download Created with Sketch. 271.26KB Share ACW Trading Halt 23/11/21 PRICE SENSITIVE download Created with Sketch. 343.76KB Share ACW ACW announces open IND for Phase 2 Fragile X trial & LOI 09/11/21 PRICE SENSITIVE download Created with Sketch. 236.09KB Share ACW Quarterly Activity Report & Appendix 4C 20/10/21 PRICE SENSITIVE download Created with Sketch. 409.13KB Share ACW R&D Tax Incentive Rebate received of A$1.435 million 13/10/21 PRICE SENSITIVE download Created with Sketch. 198.91KB Share ACW Actinogen Medical FY21 Results- Progressing the Pipeline 30/08/21 PRICE SENSITIVE download Created with Sketch. 233.75KB Share ACW Appendix 4E & Annual Report 30/08/21 PRICE SENSITIVE download Created with Sketch. 2.74MB Share ACW Actinogen completes global patent family grant 23/08/21 PRICE SENSITIVE download Created with Sketch. 194.63KB Share ACW Quarterly Activity Report & Appendix 4C 22/07/21 PRICE SENSITIVE download Created with Sketch. 284.43KB Share ACW First Patient Enrolled in XanaMIA trial 15/07/21 PRICE SENSITIVE download Created with Sketch. 187.34KB Share ACW Actinogen receives positive Pre-IND FDA advice for FXS 23/06/21 PRICE SENSITIVE download Created with Sketch. 174.43KB Share ACW Clinical progress for XanaMIA trial 21/06/21 PRICE SENSITIVE download Created with Sketch. 137.28KB Share ACW Actinogen Ethics Committee approval for XanaMIA study 02/06/21 PRICE SENSITIVE download Created with Sketch. 162.47KB Share ACW Response to ASX Price Query 24/05/21 PRICE SENSITIVE download Created with Sketch. 291.5KB Share ACW Strategic Update & Teleconference Call Notification 21/04/21 PRICE SENSITIVE download Created with Sketch. 3.02MB Share ACW Quarterly Activity Report & Appendix 4C 21/04/21 PRICE SENSITIVE download Created with Sketch. 285.3KB Share ACW Actinogen CEO assumes Managing Director position 24/03/21 PRICE SENSITIVE download Created with Sketch. 159.22KB Share ACW Actinogen appoints Dr Steven Gourlay as CEO 15/03/21 PRICE SENSITIVE download Created with Sketch. 216.74KB Share ACW Appendix 4D & Half-Year Financial Statements 24/02/21 PRICE SENSITIVE download Created with Sketch. 453.53KB Share ACW ACW raises an addtional $3.55m under a Shortfall Placement 10/02/21 PRICE SENSITIVE download Created with Sketch. 162.1KB Share ACW Resignation of Dr Bill Ketelbey as Chief Executive Officer 08/02/21 PRICE SENSITIVE download Created with Sketch. 158.41KB Share ACW FDA Grants ACW Rare Paediatric Disease Designation in FXS 05/02/21 PRICE SENSITIVE download Created with Sketch. 208.32KB Share ACW Pause in Trading 05/02/21 PRICE SENSITIVE download Created with Sketch. 115.67KB Share ACW Quarterly Activity Report & Appendix 4C 29/01/21 PRICE SENSITIVE download Created with Sketch. 244.82KB Share ACW Completion of Entitlement Offer 13/11/20 PRICE SENSITIVE download Created with Sketch. 198.25KB Share ACW Actinogen files new patent applications 09/11/20 PRICE SENSITIVE download Created with Sketch. 199.08KB Share ACW FDA IND Update 04/11/20 PRICE SENSITIVE download Created with Sketch. 161.63KB Share ACW ACW to initiate XanaFX clinical trial in Fragile X syndrome 02/11/20 PRICE SENSITIVE download Created with Sketch. 1.16MB Share ACW Quarterly Activity Report & Appendix 4C 29/10/20 PRICE SENSITIVE download Created with Sketch. 328.98KB Share ACW R&D Tax Incentive Rebate received of A$2.9 million 27/10/20 PRICE SENSITIVE download Created with Sketch. 191.49KB Share ACW Offer Booklet 23/10/20 PRICE SENSITIVE download Created with Sketch. 765.31KB Share ACW Actinogen Presentation & Planned Conference Call 15/10/20 PRICE SENSITIVE download Created with Sketch. 2.73MB Share ACW Proposed issue of Securities - ACW 15/10/20 PRICE SENSITIVE download Created with Sketch. 36.63KB Share ACW ACW announces two clinical trials & launches capital raising 15/10/20 PRICE SENSITIVE download Created with Sketch. 219.11KB Share ACW Trading Halt 13/10/20 PRICE SENSITIVE download Created with Sketch. 131.2KB Share ACW Appendix 4E & Annual Report 26/08/20 PRICE SENSITIVE download Created with Sketch. 1.05MB Share ACW Quarterly Activity Report & Appendix 4C 29/07/20 PRICE SENSITIVE download Created with Sketch. 331.08KB Share ACW Response to ASX Price Query 01/07/20 PRICE SENSITIVE download Created with Sketch. 254.37KB Share ACW Quarterly Activity Report & Appendix 4C 23/04/20 PRICE SENSITIVE download Created with Sketch. 228.75KB Share ACW Market Update COVID-19 26/03/20 PRICE SENSITIVE download Created with Sketch. 159.31KB Share ACW Appendix 4D & Half-Year Financial Statements 20/02/20 PRICE SENSITIVE download Created with Sketch. 789.69KB Share
(20min delay)
